Swapnajit Chakravarty and Ray Chen of Austin, Texas, have received US Patent No. 8,293,177, "Photonic crystal microarray device for label-free multiple analyte sensing, biosensing and diagnostic assay chips." The claimed arrays consist of photonic crystal microcavities along a single photonic crystal waveguide, according to the patent. The inventors state that the device enables the detection and identification of multiple species to be performed simultaneously using optical techniques leading to a high throughput device for chemical sensing, biosensing, and medical diagnostics.
Sumitomo Bakelite of Tokyo and Somalogic of Boulder, Colo., have received US Patent No. 8,293,190, "Polymer compound for biomedical use and biochip substrate using such a polymer compound." The patent claims a biochip substrate that contains a polymer compound layer obtained by copolymerizing an ethylenically unsaturated polymerizable monomer having an alkylene glycol residue, an ethylenically unsaturated polymerizable monomer having a functional group for fixing a biologically active substance, and an ethylenically unsaturated polymerizable monomer having a cross-linkable functional group, on the surface of the substrate. According to the patent, the substrate is capable of high-detection accuracy by restricting the nonspecific adsorption or bonding of the substance to be detected.
Cornell University of Ithaca, NY, has received US Patent No. 8,293,337, "Multiplexed electrospray deposition method." The patent describes a multiplexed electrospray deposition apparatus capable of delivering picoliter volumes of one or more substances. According to the patent, the apparatus may include a unitary planar dispenser etched from a silicon wafer through microfabrication or micromachining technology and may be used as a deposition tool for making protein microarrays in a noncontact mode.
Corning of Corning, NY, has received US Patent No. 8,293,484, "Method and device for protein delivery into cells." The claimed method includes providing a protein-containing mixture; depositing the mixture onto a surface at defined locations; affixing the mixture to the surface as microspots; and plating cells onto the surface in sufficient density and under conditions for the proteins to be delivered into the cells. According to the patent, the mixture may consist of any suitable amino acid sequence, including peptides, proteins, protein domains, antibodies, or protein-nucleic acid conjugates, with a carrier reagent. The resulting protein-transfected cell arrays may be used for screening of protein or enzymatic functions or any given intracellular protein interaction in the natural environment of a living cell, as well as for high-throughput screening of other biological and chemical analytes that affect the functions of these proteins.
CapitalBio and Tsinghua University, both of Beijing, have received US Patent No. 8,293,519, "Microarray devices having controllable reaction volume." A microarray reaction device is claimed that can be used in assaying the interaction between various moieties, such as nucleic acids, immunoreactions involving proteins, interactions between a protein and a nucleic acid, a ligand-receptor interaction, and small molecule and protein or nucleic acid interactions. Methods of manufacturing the array and kits containing it are also claimed.
X-Body of Waltham, Mass., has received US Patent No. 8,293,542, "Real time binding analysis of antigens on a biosensor surface." A method is claimed for detecting if different epitope classes of antibodies in an antibody population are present as compared to display phage, antibodies, or antibody fragments immobilized on a biosensor. It includes immobilizing display phage, antibodies, or antibody fragments to a biosensor; contacting the biosensor with a binding partner; and contacting the antibody population with the biosensor. According to the patent, a detectable signal generated by binding of the antibody population to the binding partner indicates that different epitope classes are present in the antibody population than in the immobilized display phage, antibodies, or antibody fragments.
Exiqon of Vedbaek, Denmark, has received US Patent No. 8,293,684, "Locked nucleic acid reagents for labeling nucleic acids." A method of detecting the presence of a nucleic acid of interest in a sample is claimed. It includes providing the sample; ligating a nucleic acid of interest with a specific labeling reagent claimed in the patent; providing a nucleic acid array having probes directed to the nucleic acid of interest; hybridizing the labeled nucleic acid fragments to the array; and determining the extent of hybridization to the probes to determine the presence of the nucleic acid of interest.
Progenika Biopharma and Bioiberica, both of Barcelona, have received US Patent No. 8,296,073, "Diagnostic method." A method is claimed for making a prognosis for osteoporosis and estimating osteoporosis quantitative traits based on selected SNP variables and clinical variables. Products and methods are described for genotyping multiple osteoporosis-associated genetic variations. Microarrays for in vitro genotyping of osteoporosis associated genetic variations are also described. In addition, methods for predicting and treating low bone mineral density and fractures in osteoporosis are claimed.